Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627355 | 0.93 | ALDH1A1 (0.42) | BACE1SLC1A2SLC1A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18359864 | 0.78 | ALDH1A1 (0.48) | ALDH1A1ACE | |
| SCHEMBL8472422 | 0.78 | ALDH1A1 (0.48) | ALDH1A1ACE | |
| SCHEMBL8472423 | 0.78 | ALDH1A1 (0.48) | ALDH1A1ACE | |
| SCHEMBL4564346 | 0.74 | ALDH1A1 (0.42) | ALDH1A1ACE | |
| SCHEMBL4564347 | 0.74 | ALDH1A1 (0.42) | ALDH1A1ACE | |
| SCHEMBL23099848 | 0.73 | ATM (0.42) | ALDH1A1ACE | |
| SCHEMBL10957821 | 0.73 | ATM (0.42) | ALDH1A1ACE | |
| SCHEMBL10957808 | 0.73 | ATM (0.42) | ALDH1A1ACE | |
| SCHEMBL1491418 | 0.73 | ALDH1A1 (0.43) | BACE1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | BACE1 1003/4885SLC1A2 3524/4885SLC1A1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.